-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RPI-MN in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RPI-MN in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RPI-MN in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug...
-
Product Insights
RPI – Dolni Balvan Solar Power Plant 85 MW – Karbinci
Equip yourself with the essential tools needed to make informed and profitable decisions with our RPI - Dolni Balvan Solar Power Plant 85 MW - Karbinci report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RPI-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RPI-001 Drug Details RPI-001 is under development for the treatment of wet age-related macular...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RPI-002
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RPI-002 Drug Details RPI-002 is under development for the treatment of chemotherapy induced neuropathic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RPI-MN
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RPI-MN Drug Details RPI-MN (modified cobratoxin) is under development for the treatment of human...
-
Product Insights
Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery. The Myasthenia Gravis - Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and...
-
Sector Analysis
Baby Food in Portugal
The market for baby food in Portugal has been suffering in recent years as a result of a sharp decline in the number of births. Until 2005, cereals was the largest sector in the Portuguese baby food market, but in 2006 it was overtaken by wet meals, a trend subsequently maintained. As a result, in 2015 the market divided in volume terms into 34.9% baby meals, 32.3% cereals, 32.1% baby milks, and 0.2% baby drinks and finger foods. In value...